The administration of a second dose of her vaccine Johnson & Johnson for coronavirus sets up a committee of American experts. The committee’s recommendation comes to allay the concerns of millions of Americans who had done the monopoly vaccine but they wondered if it was enough to protect them, especially after the Delta mutation spread.
The members of the committee, which met at the request of the US Food and Drug Administration (FDA), agreed, according to the Athenian-Macedonian News Agency, that the evidence regarding the safety and efficacy of the vaccine is sufficient torecommend a second dose, as the pharmaceutical industry also argued.
This recommendation may, however, be amended by FDA or from CDC, the federal Centers for Disease Control and Prevention. Urgent approval of these services may be given in the coming days or weeks.
Some of these independent experts have suggested that although J&J requested that a “booster dose” be approved, this dose should be considered “supplementary” in order to achieve a more complete vaccination. “I sincerely believe that it has always been a two-dose vaccine. “It’s complicated to recommend it as a single dose,” said Paul Ofit, an immunization specialist at Philadelphia Pediatric Hospital.
In its US study, J&J reported that the effectiveness of its vaccine against the symptomatic form of Covid-19 increased from 70% to 94% after the second dose two months after the first dose, rates that are similar to those of vaccines using messenger RNA technology (Pfizer, Moderna).
Yesterday, the committee recommended the administration of a booster dose of its vaccine Modern for vulnerable citizens, especially those over 65 and for those who, due to the nature of their work, are more at risk of being exposed to the virus. A similar decision was made several weeks ago for her vaccine Pfizer.
The J&J vaccine proposal applies to all people over the age of 18 who took the first dose at least two months ago.